These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 21638319

  • 1. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, Miller PD, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DJ.
    J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
    [Abstract] [Full Text] [Related]

  • 2. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 3. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan 01; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 4. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F.
    Clin Exp Rheumatol; 2007 Jan 01; 25(3):464-6. PubMed ID: 17631747
    [Abstract] [Full Text] [Related]

  • 5. Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.
    Tucci JR.
    Endocr Pract; 2008 Jan 01; 14(5):607-10. PubMed ID: 18753106
    [Abstract] [Full Text] [Related]

  • 6. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
    Devogelaer JP, Geusens P, Daci E, Gielen E, Denhaerynck K, Macdonald K, Hermans C, Vancayzeele S, Abraham I, Boonen S.
    Calcif Tissue Int; 2014 Mar 01; 94(3):311-8. PubMed ID: 24271562
    [Abstract] [Full Text] [Related]

  • 7. [Effect of a single dose of zoledronic acid in a case of Paget bone disease].
    Saban M, Fidalgo S, Díaz CA, Lutfi RJ.
    Medicina (B Aires); 2010 Mar 01; 70(5):445-8. PubMed ID: 20920964
    [Abstract] [Full Text] [Related]

  • 8. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar 01; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 9. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM.
    Nat Clin Pract Rheumatol; 2006 Apr 01; 2(4):186-7. PubMed ID: 16932682
    [No Abstract] [Full Text] [Related]

  • 10. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM, Scott LJ.
    Drugs; 2007 Apr 01; 67(5):793-804. PubMed ID: 17385948
    [Abstract] [Full Text] [Related]

  • 11. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone.
    Merlotti D, Rendina D, Gennari L, Mossetti G, Gianfrancesco F, Martini G, De Filippo G, Avanzati A, Franci B, Campagna MS, Strazzullo P, Nuti R.
    J Bone Miner Res; 2011 Mar 01; 26(3):512-8. PubMed ID: 20814970
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of zoledronic acid treatment in Paget disease of bone.
    Baykan EK, Saygılı LF, Erdogan M, Cetinkalp S, Ozgen AG, Yilmaz C.
    Osteoporos Int; 2014 Sep 01; 25(9):2221-3. PubMed ID: 24899102
    [Abstract] [Full Text] [Related]

  • 13. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 01; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 14. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug 01; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 15. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun 01; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 16. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy.
    Pane A.
    Arch Ophthalmol; 2007 Oct 01; 125(10):1440-1. PubMed ID: 17923566
    [No Abstract] [Full Text] [Related]

  • 17. Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
    Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
    Ann Oncol; 2007 Jul 01; 18(7):1165-71. PubMed ID: 17442659
    [Abstract] [Full Text] [Related]

  • 18. Zoledronic acid for Paget's disease of bone.
    Maricic M.
    Drugs Today (Barc); 2007 Dec 01; 43(12):879-85. PubMed ID: 18174973
    [Abstract] [Full Text] [Related]

  • 19. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A.
    J Clin Endocrinol Metab; 2013 May 01; 98(5):1911-5. PubMed ID: 23596142
    [Abstract] [Full Text] [Related]

  • 20. [Optimizing therapy in Paget disease].
    Füessl HS.
    MMW Fortschr Med; 2005 Dec 15; 147(51-52):32. PubMed ID: 16402704
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.